发布文献求助

zz

Lv5

840 积分 2025-04-22 加入

最近求助
最近应助
互助留言

Ustekinumab improves general health status and disease-specific health related quality of life of patients with moderate to severe crohn's disease: Results from the uniti and IMUNITI phase 3 clinical trials 1个月前 已完结
Ustekinumab improves general health status and disease-specific health related quality of life of patients with moderate to severe crohn's disease: Results from the uniti and IMUNITI phase 3 clinical trials 1个月前 已关闭
Endoscopic Healing in the Ustekinumab Phase 3 UNITI/IMUNITI Crohn's Disease Program and Relationship of Clinical Outcomes to Baseline Ulceration Status 1个月前 已完结
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn’s disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial 6个月前 已关闭
A multicenter, randomized, double-blind, placebo-controlled Phase2b study of ustekinumab, a human monoclonal antibody to IL-12/23p40, in patients with moderately to severely active Crohn's disease: Results through week 22 from the CERTIFI trial 6个月前 已完结

没有进行任何应助

修改求助积分【积分已退回】 1个月前
不包含求助文献 1个月前

最近帖子
最近评论

没有发布任何帖子

没有发布任何评论

Copyright © 2020-2026 AbleSci.COM, 科研通, All Right Reserved

科研通是非营利科研互助平台，不忘初心，为科研助力

本站互助的所有文件仅供个人学习研究用，禁止任何人把求助的所得文献进行盈利或传播

皖ICP备2024041134号-1

皖公网安备34019202002308

科研通【文献互助QQ群】：如果您有特殊求助，或发布求助超过24小时未得到应助，可加群求助，群号：821889395【点击一键加群】

科研通【志愿服务QQ群】：如果您热爱文献互助，有热心愿意为更多人服务，请加入小伙伴群，点击申请加入

关注微信服务号

科研通